Pitavastatin (Livalo)

Detailed overview

Pitavastatin is an HMG-CoA reductase inhibitor, so it works on the same principle as other statins: it slows hepatic cholesterol synthesis, the cell compensates by upregulating LDL receptors, and more receptors clear more LDL from the circulation. The Cochrane review (Adams 2020) confirmed dose-dependent LDL lowering. Two things separate it from the other statins, and both matter practically. The first is the metabolic route: pitavastatin is cleared predominantly by glucuronidation and largely bypasses the cytochrome P450 enzymes, particularly CYP3A4. That means substantially fewer drug interactions, a real advantage in patients on many medicines. One notable exception is ciclosporin: it inhibits the OATP1B1 transporter by which pitavastatin enters the liver, making co-administration an absolute contraindication. The second is the effect on carbohydrate metabolism. As a class, statins mildly increase the risk of new-onset diabetes. Pitavastatin stands apart here: the Barrios 2016 review reports a neutral to favourable effect on glucose and HbA1c. That matters in patients with diabetes or at risk of it. On clinical outcomes the key study is REAL-CAD (Taguchi 2018): in stable coronary artery disease the higher 4 mg dose produced better outcomes than 1 mg, confirming the general statin principle that more intensive LDL lowering delivers more.